Finasteride: Facts and Myths
DOI:
https://doi.org/10.12970/2310-998X.2015.03.01.4Keywords:
Androgenetic alopecia. Finasteride. Adverse effects. 5 alpha-reductase. Androgens.Abstract
Media reports, Internet sites and misinformation by alternative medicine practitioners recently contributed to a negative image associated with finasteride, leading to apprehension and concern among patients taking the medication. Frequently, even dermatologists seem to be hesitant to prescribe the drug for long periods, mistakenly fearing the occurrence of long-term side effects. Finasteride, either alone or in combination with topical minoxidil, is an excellent option for men with androgenetic alopecia, reducing hair loss, and/or restoring hair growth in 9 of 10 patients. The drug can be taken at any time of the day, with or without food. There are no reports of significant drug interactions or allergies. Because it is metabolized in the liver, the drug should be used with caution in patients with liver diseases, but there is no need to indicate liver function tests frequently yet.
References
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59(4): 547-66; quiz. 567-8.
Pereira JM. Alopecia Androgenética (Calvície) na Mulher. Rio de Janeiro: Ed. Di livros; 2007.
Niiyama S, Kojima K, Hamada, Happle R, Hoffmann R. The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol 2000; 10 (8): 593-5.
Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41(4): 550-4.
Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab1994; 79 (3): 703-6.
Roberts JL. Finasteride in a 1-mg dose is safe and effective. Arch Dermatol 1999; 135 (8): 990. http://dx.doi.org/10.1001/archderm.135.8.990
Camacho FM, García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. Br J Dermatol 2008; 158(5): 1121-4. http://dx.doi.org/10.1111/j.1365-2133.2008.08509.x
Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol1999; 162 (4): 1295-300. http://dx.doi.org/10.1016/S0022-5347(05)68270-5
Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007; 92 (5): 1659-65. http://dx.doi.org/10.1210/jc.2006-2203
Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl 2007; 53 (4): 229-33. http://dx.doi.org/10.1080/01485010701426471
Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril 2007; 90 (3): 849.e17-9.
Propecia [package]. Whitehouse Station, NJ: Merck & Co, Inc 2004.
Wilton L, Pearce G, Edet E, Freeemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,722 patients. Br J Urol 1996; 78 (3): 379-84. http://dx.doi.org/10.1046/j.1464-410X.1996.00091.x
Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40 (6 Pt 1): 930-7. http://dx.doi.org/10.1016/S0190-9622(99)70081-2
Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002; 29 (1): 665-9. http://dx.doi.org/10.1111/j.1346-8138.2002.tb00200.x
Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007; 4 (6): 1708-12. http://dx.doi.org/10.1111/j.1743-6109.2007.00563.x
Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J 2012; 3(1): 62-5. http://dx.doi.org/10.4103/2229-5178.93496
Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15(4): 299-306. http://dx.doi.org/10.1038/sj.ijir.3901017
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39 (4 Pt 1): 578-89. http://dx.doi.org/10.1016/S0190-9622(98)70007-6
Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12 (1): 38-49.
Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99(13): 1025-35. http://dx.doi.org/10.1093/jnci/djm023
Erdemir F, Harbin A, Hellstrom WJ. 5-alphareductase inhibitors and erectile dysfunction: the connection. J Sex Med 2008; 5 (12): 2917-24. http://dx.doi.org/10.1111/j.1743-6109.2008.01001.x
Vaughan D, Imperato-McGinley J, McConnell J, et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002; 60 (6): 1040-4. http://dx.doi.org/10.1016/S0090-4295(02)01971-4
Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99 (13): 1025-35. http://dx.doi.org/10.1093/jnci/djm023
Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg 2009; 2 (1): 12-6. http://dx.doi.org/10.4103/0974-2077.53093
Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med 2012; 9 (11): 2927-32. http://dx.doi.org/10.1111/j.1743-6109.2012.02846.x
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010; 146(10): 1141-50. http://dx.doi.org/10.1001/archdermatol.2010.256
Tu HY, Zini A. Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril 2011; 95 (6): 2125.e13-4.
Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril 2011; 95 (5): 1786.e9-11.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011; 8(3): 872-84. http://dx.doi.org/10.1111/j.1743-6109.2010.02157.x
Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004; 96 (4): 338-9. http://dx.doi.org/10.1093/jnci/djh062
Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med 1996; 335 (11): 823. http://dx.doi.org/10.1056/NEJM199609123351116
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-24. http://dx.doi.org/10.1056/NEJMoa030660
Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007; 22 (1): 107-18.
Serfling R, Shulman M, Thompson GL, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 2007; 177 (6): 2352-6. http://dx.doi.org/10.1016/j.juro.2007.01.116
Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006; 175(2): 505-9. http://dx.doi.org/10.1016/S0022-5347(05)00236-3
Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143(4): 804-10. http://dx.doi.org/10.1046/j.1365-2133.2000.03780.x
Whiting DA, Oslen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 a 60 years with male pattern hair loss. Eur J Dermatol 2003; 13 (2): 150-60.
Steiner D, Marçon CR. Finasterida: mitos e verdades. RBM Revista Brasileira de Medicina 2010; 67(10): 18-24.
Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses 2004; 62 (1): 112-5. http://dx.doi.org/10.1016/S0306-9877(03)00264-0
Arca E, Açikgöz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209 (2): 117-25. http://dx.doi.org/10.1159/000079595
